TG Therapeutics Gets European Commission Approval Of Briumvi For The Treatment Of Relapsing Forms Of Multiple Sclerosis In Adults
Portfolio Pulse from Happy Mohamed
TG Therapeutics has received European Commission approval for Briumvi, a treatment for relapsing forms of multiple sclerosis in adults. This approval could potentially expand the market for the drug.
May 31, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics' Briumvi has been approved by the European Commission for treating relapsing forms of multiple sclerosis, potentially expanding the market for the drug.
The European Commission's approval of Briumvi for the treatment of relapsing forms of multiple sclerosis in adults is a significant milestone for TG Therapeutics. This approval could potentially expand the market for the drug, leading to increased sales and revenue for the company. As a result, this news is likely to have a positive short-term impact on TGTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100